von Tobias Borgers | Okt. 1, 2021 | Bayer
Pharmaceutical giant Bayer has awarded MediaCom its $800 million global media account following a competitive review. The WPP agency previously handled the majority of Bayer’s media planning and buying across 65 markets, but has now added other parts of the...
von Tobias Borgers | Okt. 1, 2021 | Bayer
German pharma giant Bayer hasn’t had a major presence in San Diego. But its multi-billion dollar acquisition of Sorrento Valley biotech Vividion Therapeutics just changed all that. Vividion had been planning to go public when Bayer offered it up to $2 billion in...
von Tobias Borgers | Sep. 28, 2021 | Bayer
Danish biotech Gubra will help German neighbor Bayer find new peptide treatments for kidney and heart disorders in a biobucks deal worth up to 216 million euros ($253 million). The Big Pharma will collaborate with Gubra on researching potential drugs for cardiorenal...
von Tobias Borgers | Sep. 23, 2021 | Bayer
Über Finerenon Finerenon (BAY 94-8862) ist ein nicht-steroidaler und selektiver Antagonist des Mineralokortikoid-Rezeptors (MR), der in präklinischen Studien gezeigt hat, dass er schädliche Wirkungen einer Überaktivierung des Mineralokortikoid-Rezeptors (MR) hemmt. Es...
von Tobias Borgers | Sep. 21, 2021 | Bayer
In a bid to quickly broaden its drug discovery abilities, Bayer (BAYRY) has reached a deal to acquire Vividion Therapeutics for $1.5 billion, the third time in two years the company has bought a small biotech with proprietary technology for uncovering...
von Tobias Borgers | Sep. 11, 2021 | Bayer
Onkologie bei Bayer Mit dem Ziel, das Leben von Menschen zu verbessern, arbeitet Bayer an der Erweiterung seines Portfolios für innovative Behandlungen. Der Forschungsansatz des Unternehmens priorisiert Ansätze, die das Potenzial haben, das Leben von Menschen...
